Free Trial
→ This is the worst news for stocks in 50 years (From TradeSmith) (Ad)tc pixel
NASDAQ:ZSQR

Coeptis Therapeutics Q3 2025 Earnings Report

Coeptis Therapeutics logo
$10.93 +0.03 (+0.28%)
As of 06/12/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Coeptis Therapeutics EPS Results

Actual EPS
-$0.58
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Coeptis Therapeutics Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Coeptis Therapeutics Announcement Details

Quarter
Q3 2025
Date
11/13/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Coeptis Therapeutics Earnings Headlines

Coeptis Therapeutics (NASDAQ:ZSQR) Downgraded to "Sell" Rating by Wall Street Zen
June 13 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30835916
Z Squared to Participate in Maxim Group's AI Data Center Summit
June 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/z-squared-to-participate-in-maxim-groups-ai-data-center-summit-302794415.html
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
 |  Profits Run (Ad)
Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure Buildout
June 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/z-squared-inc-enters-50-million-committed-equity-forward-purchase-agreement-to-support-ai-infrastructure-buildout-302791528.html
Z Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes
May 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/z-squared-inc-announces-preliminary-inclusion-in-russell-3000-and-russell-2000-indexes-302782976.html
Vanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready Power
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301053/0/en/vanderbilt-report-z-squared-locks-in-zero-cash-zero-debt-path-to-42-mw-of-ai-ready-power.html
See More Coeptis Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coeptis Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coeptis Therapeutics and other key companies, straight to your email.

About Coeptis Therapeutics

Coeptis Therapeutics (NASDAQ:ZSQR), a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

View Coeptis Therapeutics Profile
Earnings Tools